Bmab1700
Monoclonal antibody
Evidence outlook
Early-stage evidence only
Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT07476326 NCT07476326 · Melanoma Registry: NCT07476326 | 1 | Area Under the Concentration-Time Curve from Time 0 (Day 1) To Day 29 After the First Dose (AUC0-28days) of Bmab 1700 and Opdivo (Week 0 through Week 4); Area Under the Concentration-Time Curve Over a Dosing Interval (AUC0-tau) of Bmab 1700 and Opdivo (Week 16 through Week 20) 2027-08-16 | In progress: results expected 16 Aug 2027 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 1 (1)
What this study did
Competitive landscape
Other PD-1 drugs
Cemiplimab, Dostarlimab, Nivolumab, Opdivo Qvantig, Pembrolizumab and 21 more. Compare all 27 PD-1 drugs
This mechanism is crowded: 26 other tracked programmes target it, 26 of them ahead of this one.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Bmab1700: this drug | Phase 1 | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary | |
| Cemiplimab | Approved(overall) | Monoclonal antibody | PD-1 | Partial signal | NCT03088540: Overall Survival (OS) (Up to 94 months): Cemiplimab 23.4 months (95% CI 19.4 to 27.6) vs Chemotherapy 13.7 months (95% CI 11.2 to 16.2) NCT03409614: Part 1: Overall Survival (OS) (Up to a maximum of 82.2 months): Part 1: Cemiplimab + Chemotherapy 15.9 months (95% CI 11.7 to 24.2) | Part 1: Cemiplimab+AbbrevChemo+Ipilimumab 20.1 months (95% CI 13.7 to 28.3) vs Part 1: Chemotherapy 13.9 months (95% CI 10 to 17.7) | |
| Dostarlimab | Approved(overall) | Monoclonal antibody | PD-1 | Partial signal | NCT03602859: Progression Free Survival (PFS) (Up to approximately 316 weeks): Paclitaxel + Carboplatin + Dostarlimab Pbo +/- Bev, Then Niraparib+Dostarlimab Pbo +/- Bev (Arm2) 19.19 Months (95% CI 16.59 to 20.99) | Paclitaxel + Carboplatin + Dostarlimab +/- Bev, Then Niraparib+Dostarlimab +/- Bev (Arm3) 20.63 Months (95% CI 19.22 to 22.77) NCT04655976: Overall Survival (OS) (Arm A Versus Arm C) (Up to approximately 234 weeks): Cobolimab + Dostarlimab + Docetaxel (Arm A) 11.9 Months (95% CI 10.6 to 14.2) vs Docetaxel (Arm C) 11.3 Months (95% CI 9.5 to 13.9) missed | |
| Nivolumab | Approved(overall) | Monoclonal antibody | PD-1 | Reliable signal | NCT02388906: Recurrence-free Survival (RFS) (up to 36 months): Nivolumab 3 mg/kg 52.37 Months | Ipilimumab 10 mg/kg 24.08 Months (95% CI 16.56 to 35.09) NCT03036098: Sub-study (cisplatin-eligible), nivolumab + gemcitabine-cisplatin vs gemcitabine-cisplatin: PFS HR 0.72 (95% CI 0.59 to 0.88), p=0.0018; OS median 21.7 vs 18.9 months, HR 0.78 (95% CI 0.63 to 0.96), p=0.0171. Primary study, nivolumab + ipilimumab vs chemotherapy: OS in PD-L1 >=1% 16.3 vs 14.4 months, primary not met per BMS; OS in cisplatin-ineligible 19.1 vs 13.2 months, HR 0.79 (95% CI 0.64 to 0.97), posted p=0.0032 (CT.gov posted results). | |
| Opdivo Qvantig | Approved(overall) | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary | |
| Pembrolizumab | Approved(overall) | Monoclonal antibody | PD-1 | Reliable signal | NCT03914612: PFS with pembrolizumab plus paclitaxel/carboplatin vs placebo plus chemotherapy: dMMR cohort 12-month PFS 74% vs 38% (HR 0.30, 95% CI 0.19 to 0.48, P<0.001); pMMR cohort median 13.1 vs 8.7 months (HR 0.54, 95% CI 0.41 to 0.71, P<0.001) (NRG-GY018, NEJM 2023). NCT04003636: Overall Survival (OS) (Up to approximately 38 months): Arm A: Pembrolizumab + Chemotherapy 12.7 Months (95% CI 11.5 to 13.6) | Arm B: Placebo + Chemotherapy 10.9 Months (95% CI 9.9 to 11.6) | |
| Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex) | Approved(overall) | Monoclonal antibody | PD-1 | Partial signal | Featured results are non-efficacy only | |
| Penpulimab | Approved(overall) | Monoclonal antibody | PD-1 | Reliable signal | NCT03866993: Primary 1, IRRC-assessed PFS in the ITT population (final analysis): median 7.6 months (95% CI 6.8 to 9.6) penpulimab + chemotherapy vs 4.2 months (95% CI 4.2 to 4.3) placebo + chemotherapy; HR 0.43 (95% CI 0.33 to 0.56); p<0.0001, met. Primary 2, IRRC-assessed PFS in the PD-L1-positive subgroup: median 8.1 vs 4.2 months; HR 0.37 (95% CI 0.27 to 0.52); p<0.0001, met. | |
| Retifanlimab | Approved(overall) | Monoclonal antibody | PD-1 | Reliable signal | NCT04205812: Overall Survival (up to 39.1 months): Retifanlimab + Chemotherapy 18.1 months (95% CI 16.2 to 21) vs Placebo + Chemotherapy 13.4 months (95% CI 11 to 16.7) | |
| Tislelizumab | Approved(overall) | Monoclonal antibody | PD-1 | Partial signal | NCT03957590: Progression-free Survival (PFS) (From randomization to the prespecified primary analysis data cut-off date of 08 January 2025; maximum time on study was 67 months.): Tislelizumab + Chemoradiotherapy 29 months | Placebo + Chemoradiotherapy 28.9 months missed NCT03412773: Overall survival, tislelizumab vs sorafenib: median 15.9 vs 14.1 months, hazard ratio 0.85 (95.003% CI 0.712 to 1.019); upper bound below the 1.08 non-inferiority margin, so non-inferior; superiority not shown (one-sided p=0.0398 vs boundary 0.0223) (CT.gov posted results). | |
| Toripalimab | Approved(overall) | Monoclonal antibody | PD-1 | Reliable signal | NCT04158440: Primary, investigator-assessed EFS in the stage III population (interim analysis, n=404): median not estimable vs 15.1 months, toripalimab + chemotherapy vs placebo + chemotherapy; HR 0.40 (95% CI 0.28 to 0.57); P<.001, met. Primary, BIPR-assessed MPR rate in the stage III population: 48.5% vs 8.4% (difference 40.2%, 95% CI 32.2% to 48.1%; P<.001), met. Primaries, EFS and MPR rate in the stage II-III population (final analysis): the sponsor states both met the pre-defined efficacy boundary; figures not yet published, met. NCT04085276: PFS in the intent-to-treat population (this trial's stated primary analysis population): median 8.4 vs 6.9 months, HR 0.77, P=0.0445, toripalimab+nab-paclitaxel vs placebo+nab-paclitaxel. Also reported for the PD-L1-positive population: median 8.4 vs 5.6 months, HR 0.653, 95% CI 0.470-0.906, P=0.0102 | |
| Abp 234 | Phase 3(overall) | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary | |
| BAT3306 | Phase 3(overall) | Monoclonal antibody | PD-1 | Partial signal | No reviewed efficacy summary | |
| Camrelizumab | Phase 3(overall) | Monoclonal antibody | PD-1 | Partial signal | NCT04613674: Pathological complete response: 56.8% (126/222) camrelizumab+chemotherapy vs 44.7% (98/219) placebo+chemotherapy; rate difference 12.2% (95% CI 3.3%-21.2%), 1-sided P=.004 NCT03134872: Primary 1, BICR-assessed PFS in all treated randomized patients (interim analysis): median 11.3 vs 8.3 months, camrelizumab plus carboplatin and pemetrexed vs carboplatin and pemetrexed; HR 0.60 (95% CI 0.45 to 0.79); one-sided p=0.0001, met. Primary 2, BICR-assessed PFS in PD-L1-positive patients: no confirmatory test reported. | |
| Cetrelimab | Phase 3(overall) | Monoclonal antibody | PD-1 | Weak signal | Featured results are safety only | |
| CT-P51 | Phase 3(overall) | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary | |
| Enlonstobart | Phase 3(overall) | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary | |
| Iparomlimab (QL1604) | Phase 3(overall) | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary | |
| MB12 | Phase 3(overall) | Monoclonal antibody | PD-1 | Partial signal | No reviewed efficacy summary | |
| Serplulimab | Phase 3(overall) | Monoclonal antibody | PD-1 | Reliable signal | NCT04033354: At the final analysis, serplulimab plus chemotherapy significantly improved median OS compared to placebo plus chemotherapy (HR 0.73, 95% CI 0.58-0.93; p=0.010); at the second interim analysis, the PFS benefit was maintained in the serplulimab-chemotherapy group (HR 0.53, 95% CI 0.42-0.67). NCT03952403: Final analysis in nonsquamous NSCLC: median overall survival reached 26.8 months for Hetronifly (serplulimab) plus chemotherapy compared with 20.3 months for chemotherapy alone, a 34% reduction in the risk of death (HR=0.66, 95% CI: 0.52-0.83, P<0.001); median PFS was 11.0 months in Group B versus 5.7 months in the chemotherapy-only arm. No statistical difference was observed for Group A compared to Group B (HR=1.12, p=0.3628). | |
| Sintilimab | Phase 3(overall) | Monoclonal antibody | PD-1 | Partial signal | NCT03150875: Overall survival: sintilimab median 11.79 vs docetaxel 8.25 months (HR 0.74, 95% CI 0.56 to 0.96, P=0.025) (ORIENT-3, Cancer Commun 2022). NCT03607539: Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Independent Radiographic Review Committee (IRRC) (Trough Database Cutoff Date of 15-Nov-2019 (Up to approximately 16 months)): Sintilimab Combination 8.9 Months (95% CI 7.1 to 11.3) vs Placebo Combination 5 Months (95% CI 4.8 to 6.2) | |
| Budigalimab | Phase 2/3(overall) | Monoclonal antibody | PD-1 | not yet graded | NCT03000257: Phase 1 dose-escalation confirmed tolerability and linear PK; RP2D established | |
| Sasanlimab | Phase 2/3(overall) | Monoclonal antibody | PD-1 | Partial signal | Featured results are dose-finding only | |
| Balstilimab | Phase 2(overall) | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary | |
| SHR-3045 | Phase 2(overall) | Undisclosed | PD-1 | not yet graded | No reviewed efficacy summary | |
| IOV-4001 | Phase 1/2(overall) | Cell therapy | PD-1 | not yet graded | No reviewed efficacy summary | |
| OSE-279 | Phase 1/2(overall) | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Bmab1700 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.